PMID- 30124214
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20181114
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 43
IP  - 7
DP  - 2018 Jul 28
TI  - [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori 
      eradication in patients with history of antibiotic treatment].
PG  - 772-778
LID - 10.11817/j.issn.1672-7347.2018.07.012 [doi]
AB  - To investigate the efficacy of bismuth containing quadruple therapies on 
      Helicobacter pylori (Hp) eradication in patients with history of antibiotic 
      treatment. 
 Methods: Hp infected patients (n=327) were allocated into 3 groups. 
      Group A (n=52), patients had no antibiotic history and they took medicine of 
      proton pump inhibitors (PPI) and livzon triple (clarithromycin, tinidazole, and 
      bismuth); group B (n=80), patients had the antibiotic history except for 
      amoxicillin and clarithromycin, and they were treated with PPI, amoxicillin, 
      clarithromycin, and bismuth; group C (n=195), patients suffered failures of Hp 
      therapy or with history of antibiotic abuse, and they were treated with PPI, 
      doxycycline, furazolidone, and bismuth.
 Results: Both the intention-to-treat 
      (ITT) analysis (group A 63.5%, group B 76.2%, group C 82.6%, P<0.05) and the 
      pre-protocol (PP) analysis (group A 76.7%, group B 92.4%, group C 96.4%, P<0.05) 
      showed significant difference among the 3 groups, revealing higher elimination in 
      group B and C. The side-effects (20.2%) were mild and tolerable (group A, 28.0%; 
      group B, 10.7%; group C, 22.0%).
 Conclusion: Proton pump inhibitors together 
      with the livzon triple regimen have a low rate of Hp eradication and a higher 
      incidence of adverse reactions. The quadruple therapy containing clarithromycin 
      and metronidazole drugs can achieve the satisfactory outcomes based on patient's 
      antibiotic history. For patients with multiple antibiotics, the quadruple therapy 
      containing furazolidone and doxycycline may achieve the satisfactory outcomes, 
      but the adverse resction would be relatively higher.
FAU - Tang, Dan
AU  - Tang D
AD  - Department of Gastroenterology, Third Xiangya Hospital, Central South University, 
      Changsha 410013, China.
FAU - Yuan, Lingzhi
AU  - Yuan L
AD  - Department of Gastroenterology, Third Xiangya Hospital, Central South University, 
      Changsha 410013, China.
FAU - Yue, Chun
AU  - Yue C
AD  - Department of Gastroenterology, Third Xiangya Hospital, Central South University, 
      Changsha 410013, China.
FAU - Cai, Ting
AU  - Cai T
AD  - Department of Gastroenterology, Third Xiangya Hospital, Central South University, 
      Changsha 410013, China.
FAU - Yao, Yao
AU  - Yao Y
AD  - Department of Gastroenterology, Third Xiangya Hospital, Central South University, 
      Changsha 410013, China.
FAU - Wang, Fen
AU  - Wang F
AD  - Department of Gastroenterology, Third Xiangya Hospital, Central South University, 
      Changsha 410013, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. 
      Medical sciences
JID - 101230586
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 033KF7V46H (Tinidazole)
RN  - 140QMO216E (Metronidazole)
RN  - 5J9CPU3RE0 (Furazolidone)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Bismuth/*therapeutic use
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination/methods
MH  - Furazolidone/therapeutic use
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Metronidazole/therapeutic use
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Tinidazole/therapeutic use
MH  - Treatment Outcome
EDAT- 2018/08/21 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/08/21 06:00
PHST- 2018/08/21 06:00 [entrez]
PHST- 2018/08/21 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
AID - 10.11817/j.issn.1672-7347.2018.07.012 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Jul 28;43(7):772-778. doi: 
      10.11817/j.issn.1672-7347.2018.07.012.